Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 621.40M P/E - EPS this Y 5.60% Ern Qtrly Grth -
Income -81.44M Forward P/E -8.07 EPS next Y -24.20% 50D Avg Chg -4.00%
Sales - PEG 0.72 EPS past 5Y - 200D Avg Chg 24.00%
Dividend N/A Price/Book 2.50 EPS next 5Y -21.10% 52W High Chg -26.00%
Recommedations 1.70 Quick Ratio 36.19 Shares Outstanding 52.81M 52W Low Chg 165.00%
Insider Own 4.64% ROA -18.57% Shares Float 16.22M Beta 1.02
Inst Own 98.53% ROE -26.50% Shares Shorted/Prior 2.40M/2.21M Price 14.60
Gross Margin - Profit Margin - Avg. Volume 76,406 Target Price 27.67
Oper. Margin - Earnings Date Aug 7 Volume 42,123 Change 1.39%
About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences, Inc. News
11/13/24 Tyra Biosciences to Present at Upcoming Investor Conferences
11/07/24 Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
11/03/24 Chief Financial Officer of Tyra Biosciences Alan Fuhrman Buys 284% More Shares
10/28/24 Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
10/24/24 Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
10/23/24 Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
10/20/24 Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation
10/18/24 BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
10/16/24 Boxer Capital, LLC Increases Stake in Tyra Biosciences Inc
10/11/24 Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
09/11/24 Tyra Biosciences to Present at the 2024 Cantor Global Healthcare Conference
09/10/24 Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer
09/09/24 Wall Street Analysts Think Tyra Biosciences (TYRA) Could Surge 27.88%: Read This Before Placing a Bet
08/27/24 Tyra Biosciences, Inc. (TYRA): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
08/07/24 Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
07/02/24 Tyra Biosciences Announces Preclinical Proof-of-Concept Results with TYRA-300 in Hypochondroplasia (HCH)
06/23/24 Does This Valuation Of Tyra Biosciences, Inc. (NASDAQ:TYRA) Imply Investors Are Overpaying?
06/07/24 Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
06/07/24 Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
05/13/24 Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
TYRA Chatroom

User Image FomoMoFo1 Posted - 1 day ago

$TYRA not buying this is the biggest thing you will regret!!! BUY!

User Image FomoMoFo1 Posted - 2 days ago

$TYRA buy this with all you might and money and thank me by the end of the week

User Image BioStick123 Posted - 5 days ago

$URGN can anyone comment on whether $TYRA TYRA-300 is a competitor to UGN-102

User Image TxSicario Posted - 1 week ago

$TYRA is she running finally?

User Image insiderbuyingselling Posted - 1 week ago

$TYRA new insider selling: 11569 shares. http://insiderbuyingselling.com/?t=TYRA

User Image insiderbuyingselling Posted - 2 weeks ago

$TYRA new insider buying: 9500 shares. http://insiderbuyingselling.com/?t=TYRA

User Image Maxton_B Posted - 10/30/24

$TYRA ⚡️ Wild moves, no solid base. This one’s a gamble. Watch MYNZ! 75M EU, German-backed $1.5M, US deals teased. Petra Mainz hints BIG news. In 1-2 weeks, $10-50 & RS canceled.

User Image swingingtech Posted - 10/29/24

$XRX $TYRA $V https://wallstreetwaves.com/tuesdays-highlighted-options-activity-xrx-tyra-v/

User Image Fugazi_ Posted - 10/29/24

$TYRA news?

User Image _www_larval_com_ Posted - 10/29/24

$ATNF 3%[6%] $AREB 3%[12%] $UAVS -3%[5%] $GREE 3%[17%] $TYRA -3%[-16%] most notable movement into the final minutes of trading.

User Image BigBri217 Posted - 10/29/24

$TYRA wow. I really wish I had given the money I lost here away. Just terrible

User Image VictorVVV Posted - 10/29/24

$TYRA ai nvest data for Monday.

User Image BigBri217 Posted - 10/28/24

$TYRA what is going on?

User Image RealJamesGrove Posted - 10/28/24

$SHIB.X $TYRA I’m in. This could get very interesting. 🤔

User Image briefingcom Posted - 10/28/24

$TYRA: Tyra Biosciences receives IND clearance from FDA to proceed with Phase 2 Study of TYRA-300 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241028070548TYRA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image ChartLaboratory_com Posted - 10/28/24

🚀 $TBBK is at $47.01! Watch for a potential bounce back to $50.00! 📈 www.patreon.com/chartlab 💡 $ANAB trading at $32.03! Look for a move toward $34.00! Don’t miss this chance! 🚀 www.patreon.com/chartlab 📈 $VIST just hit $52.93! Targeting a rise to $54.00! Keep an eye on this one! 🔍 www.patreon.com/chartlab 🌟 $TYRA at $21.93 with a potential recovery to $24.00! Watch closely! 🔥 www.patreon.com/chartlab 📊 $ZK moving at $28.85! Targeting a push to $30.00! Don't overlook this! 🔥 www.patreon.com/chartlab https://www.patreon.com/posts/chartlab-daily-114861855?utm_medium=clipboard_copy&utm_source=copyLink&utm_campaign=postshare_creator&utm_content=join_link

User Image ChartLaboratory_com Posted - 10/28/24

🚀 $EVLV is at $2.47! Watch for a potential target of $3.00! 📈 www.patreon.com/chartlab 🔥 $TTOO trading at $1.08! Aiming for $1.30 ahead! Don’t miss out! 🚀 www.patreon.com/chartlab 💡 $JOBY just hit $5.16! Targeting a bounce to $5.50! 📊 www.patreon.com/chartlab 📈 $MNPR at $16.93 with a bounce target of $18.00! Keep an eye on this one! 👀 www.patreon.com/chartlab 🌟 $TYRA is moving! Currently $21.93, aiming for $24.00! Don't overlook this! 🔍 www.patreon.com/chartlab

User Image OpenOutcrier Posted - 10/28/24

$TYRA (+5.3% pre) FDA clears Tyra Biosciences' trial for dwarfism drug - inv https://ooc.bz/l/45933

User Image DonCorleone77 Posted - 10/28/24

$TYRA Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300 Tyra Biosciences announced that the FDA cleared its Investigational New Drug application for Tyra-300 allowing the company to proceed with a Phase 2 clinical trial of Tyra-300 for children with achondroplasia. TYRA-300 is a potential first-in-class, investigational, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4. Tyra-300 is also being evaluated for metastatic urothelial cancer in the ongoing SURF301 study. BEACH301 will be a Phase 2 study evaluating Tyra-300 in children ages 3 to 10 with achondroplasia with open growth plates. The primary objectives of this study will be to assess safety and tolerability in children with achondroplasia and evaluate change from baseline in annualized growth velocity to determine the dose for further development. Tyra is also planning exploratory assessments of clinical outcomes such as functional improvements, changes in the spine, and quality of life measures. In July 2023 and January 2024, the FDA granted Orphan Drug Designation and Rare Pediatric Designation to Tyra-300, respectively, for the treatment of achondroplasia.

User Image justiceforb_85 Posted - 10/25/24

$TYRA wondering if the company will have a MOAT? Appears they are targeting some diseases (achondroplasia, bladder, urothelial carcinoma) with approved therapies...?

User Image GambitMentality Posted - 10/25/24

Today’s #StockMarket EOD Biggest Losers by %, led by $CPRI down 48%, $MNPR down 48%, and $TYRA down 23% to lead the TOP 3

User Image BPharmCatalyst Posted - 10/25/24

$ITRM announced that the FDA has approved Iterum's new drug application for ORLYNVAH (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) Read more👇 https://www.biopharmcatalyst.com/news/2024/iterum-itrm-fda-approval-marinus-mrns-analyst $ITRM $MRNS $IBRX $LYEL $TYRA

User Image BigBri217 Posted - 10/25/24

$TYRA why is this tanking?

User Image RealJamesGrove Posted - 10/25/24

$SHIB.X anyone else see this? 100% Buy? For $TYRA? 🤔

User Image OpenOutcrier Posted - 10/25/24

$TYRA (-4.2% pre) Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cance - SI https://ooc.bz/l/45771

User Image themacromindset Posted - 10/25/24

$TYRA Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

User Image OpenOutcrier Posted - 10/24/24

$TYRA (+7.9% pre) Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET https://ooc.bz/l/45683

User Image Fugazi_ Posted - 10/24/24

$TYRA data? Trading at 31.31

User Image insiderbuyingselling Posted - 10/22/24

$TYRA new insider selling: 62720 shares. http://insiderbuyingselling.com/?t=TYRA

User Image PeedyWeedy Posted - 10/22/24

$TYRA Is data on the 25th a big mover likely?

Analyst Ratings
Oppenheimer Outperform Sep 19, 24
Piper Sandler Overweight Aug 15, 24
Wedbush Outperform Aug 8, 24
Oppenheimer Outperform Aug 8, 24
Oppenheimer Outperform Jul 3, 24
Wedbush Outperform Jul 3, 24
HC Wainwright & Co. Buy Jul 3, 24
HC Wainwright & Co. Buy Jun 5, 24
Oppenheimer Outperform May 13, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Feb 02 Sell 17.15 90,806 1,557,323 462,568 02/06/24
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Feb 02 Option 0.61 25,393 15,490 553,374 02/06/24
Harris Todd President and CEO President and CEO Feb 02 Sell 16.82 100,000 1,682,000 1,502,697 02/06/24
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 19 Sell 16.04 4,107 65,876 527,981 07/21/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 19 Option 0.61 4,107 2,505 531,881 07/21/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 13 Sell 16.08 2,400 38,592 527,981 07/17/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 13 Option 0.61 2,400 1,464 529,881 07/17/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 10 Option 0.61 1,903 1,161 528,182 07/12/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 10 Sell 16.09 1,903 30,619 527,981 07/12/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 29 Sell 16.7 40,365 674,096 527,981 07/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 29 Option 0.61 40,365 24,623 532,246 07/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 26 Sell 16.89 46,784 790,182 527,981 06/28/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 26 Option 0.61 46,784 28,538 541,505 06/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 17.16 24,190 415,100 1,601,276 06/26/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 16 Sell 17.23 75,810 1,306,206 1,625,466 06/21/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 13 Sell 16.07 20,700 332,649 1,701,276 06/15/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 13 Option 2.25 20,700 46,575 1,714,049 06/15/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 13 Sell 16.2 18,340 297,108 527,981 06/15/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 13 Option 0.61 18,340 11,187 540,573 06/15/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Apr 03 Sell 16.13 2,000 32,260 1,701,276 04/05/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Apr 03 Option 2.25 2,000 4,500 1,703,276 04/05/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 30 Sell 16.06 4,400 70,664 527,981 04/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 30 Option 0.61 4,400 2,684 529,981 04/03/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 29 Sell 16.08 4,327 69,578 1,701,276 03/31/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 29 Option 2.25 4,327 9,736 1,701,776 03/31/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 27 Sell 16.07 13,581 218,247 527,981 03/29/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 27 Option 0.61 13,581 8,284 530,168 03/29/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 24 Sell 16 5,912 94,592 1,701,276 03/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 24 Option 2.25 5,912 13,302 1,704,055 03/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 21 Sell 16 19,236 307,776 1,701,276 03/23/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 21 Option 2.25 19,236 43,281 1,704,076 03/23/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 21 Sell 16 22,727 363,632 527,981 03/23/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 21 Option 0.61 22,727 13,863 532,808 03/23/23
MVA Investors, LLC 10% Owner 10% Owner Feb 09 Sell 13.25 265,568 3,518,776 22,527 02/13/23